Enliven Therapeutics, Inc./$ELVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Ticker
$ELVN
Sector
Primary listing
Employees
61
Headquarters
Website
ELVN Metrics
BasicAdvanced
$2.8bn
-
-$1.65
0.45
-
Price and volume
Market cap
$2.8bn
Beta
0.45
52-week high
$48.53
52-week low
$14.79
Average daily volume
1.1m
Financial strength
Current ratio
40.318
Quick ratio
39.384
Total debt to equity
0.067
Profitability
EBITDA (TTM)
-115.585
Management effectiveness
Return on assets (TTM)
-18.86%
Return on equity (TTM)
-26.64%
Valuation
Price to book
6.2
Price to tangible book (TTM)
6.2
Price to free cash flow (TTM)
-42.086
Free cash flow yield (TTM)
-2.38%
Free cash flow per share (TTM)
-1.096
Growth
Earnings per share change (TTM)
-14.59%
3-year earnings per share growth (CAGR)
-35.73%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs